Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 85,895 Shares of Stock

Posted by John Perry on May 20th, 2026

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) Director Luke Evnin sold 85,895 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $0.43, for a total transaction of $36,934.85. Following the completion of the transaction, the director directly owned 955,447 shares of the company’s stock, valued at approximately $410,842.21. This represents a 8.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

On Tuesday, May 19th, Luke Evnin sold 62,970 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.45, for a total transaction of $28,336.50.
On Monday, May 18th, Luke Evnin sold 22,184 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.50, for a total transaction of $11,092.00.
On Tuesday, May 12th, Luke Evnin sold 67,885 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total transaction of $43,446.40.
On Monday, May 11th, Luke Evnin sold 33,948 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.67, for a total transaction of $22,745.16.
On Friday, May 8th, Luke Evnin sold 305,741 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.70, for a total transaction of $214,018.70.
On Thursday, May 7th, Luke Evnin sold 79,086 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total transaction of $49,824.18.
On Wednesday, May 6th, Luke Evnin sold 14,635 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.66, for a total transaction of $9,659.10.
On Tuesday, May 5th, Luke Evnin sold 6,860 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.69, for a total transaction of $4,733.40.
On Monday, May 4th, Luke Evnin sold 47,963 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.72, for a total transaction of $34,533.36.
On Friday, May 1st, Luke Evnin sold 58,394 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.73, for a total transaction of $42,627.62.

Werewolf Therapeutics Price Performance

HOWL stock traded up $0.01 during midday trading on Wednesday, hitting $0.44. 1,033,082 shares of the stock traded hands, compared to its average volume of 460,756. The firm has a market cap of $21.29 million, a P/E ratio of -0.35 and a beta of 0.41. The stock’s fifty day simple moving average is $0.80 and its 200-day simple moving average is $0.79. Werewolf Therapeutics, Inc. has a 1-year low of $0.40 and a 1-year high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.04. On average, research analysts predict that Werewolf Therapeutics, Inc. will post -1.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Wall Street Zen lowered shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $3.75.

Read Our Latest Stock Report on HOWL

Institutional Trading of Werewolf Therapeutics

Several institutional investors have recently modified their holdings of the stock. Bank of America Corp DE grew its position in shares of Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after purchasing an additional 25,882 shares during the period. Vanguard Group Inc. boosted its position in Werewolf Therapeutics by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after acquiring an additional 109,796 shares during the last quarter. Renaissance Technologies LLC boosted its position in Werewolf Therapeutics by 48.6% during the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after acquiring an additional 221,766 shares during the last quarter. Jane Street Group LLC acquired a new position in Werewolf Therapeutics during the second quarter worth about $409,000. Finally, Citadel Advisors LLC acquired a new position in Werewolf Therapeutics during the third quarter worth about $304,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

About Werewolf Therapeutics

(Get Free Report)

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.